ArticleMarine drugs2020
Characterization of a New Mixture of Mono-Rhamnolipids Produced by
Article in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Rhamnolipid-augmented medium enhances growth ofApplied and environmental microbiology · 2026Article
- Ranalexin-1G: A Promising Antimicrobial Peptide Targeting Virulence and Host-Pathogen Interactions inAntibiotics (Basel, Switzerland) · 2026Article
- Evaluation of the Emulsification Properties of Marine-Derived Rhamnolipids for Encapsulation: A Comparison with Commercial Surfactants.Biomolecules · 2025Article
- The inhibitory potential of three scorpion venom peptides against multidrug-resistantFrontiers in microbiology · 2025Article
- Integrated genome and metabolome mining unveiled structure and biosynthesis of novel lipopeptides from a deep-sea Rhodococcus.Microbial biotechnology · 2024Article
- Microbe cultivation guidelines to optimize rhamnolipid applications.Scientific reports · 2024Article
- Article
- New Imidazolium Alkaloids with Broad Spectrum of Action from the Marine BacteriumPharmaceutics · 2023Article
- Evaluation of Antimicrobial Properties and Potential Applications ofPharmaceutics · 2023Article
- Pseudomonas veronii strain 7-41 degrading medium-chain n-alkanes and polycyclic aromatic hydrocarbons.Scientific reports · 2022Article
- Rhamnolipid Nano-Micelles Inhibit SARS-CoV-2 Infection and Have No Dermal or Eye Toxic Effects in Rabbits.Antibiotics (Basel, Switzerland) · 2022Article
- Current research on simultaneous oxidation of aliphatic and aromatic hydrocarbons by bacteria of genus Pseudomonas.Folia microbiologica · 2022Review
- Antiviral Activity of the Rhamnolipids Mixture from the Antarctic BacteriumPharmaceutics · 2021Article
- Prevalence and Antibiotic Resistance Profile of Bacterial Pathogens in Aerobic Vaginitis: A Retrospective Study in Italy.Antibiotics (Basel, Switzerland) · 2021Article
- Combining OSMAC Approach and Untargeted Metabolomics for the Identification of New Glycolipids with Potent Antiviral Activity Produced by a MarineInternational journal of molecular sciences · 2021Article
- Outer Membrane Vesicles Derived fromMicroorganisms · 2020Article
- Novel Bioformulations Developed fromPlants (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
Rhamnolipids (RLs) are surface-active molecules mainly produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.